Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
| Title: | Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study) |
|---|---|
| Authors: | Dowling, Gavin P.Aff1, Aff2, IDs12885024118514_cor1; Toomey, SineadAff1; Bredin, PhilipAff1, Aff2; Parker, ImeldaAff3; Mulroe, EibhlinAff3; Marron, JacintaAff3; McLoughlin, OliviaAff3; Teiserskiene, AusraAff3; Power, ColmAff1, Aff2; O’Shea, Anne MarieAff2; Greally, MeganAff2; Morris, Patrick G.Aff1, Aff2; Duke, DeirdreAff1, Aff2; Hill, Arnold D. K.Aff1, Aff2; Hennessy, Bryan T.Aff1, Aff2 |
| Source: | BMC Cancer. 24(1) |
| Database: | Springer Nature Journals |